Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8687999 | 0.78 | IDO1 (0.42) | IDO1ADRA2AADRA2B | |
| SCHEMBL8689417 | 0.78 | IDO1 (0.43) | IDO1ADRA2AADRA2B | |
| SCHEMBL8687758 | 0.76 | IDO1 (0.39) | IDO1ADRA2AADRA2B | |
| SCHEMBL8687672 | 0.75 | IDO1 (0.48) | IDO1ADRA2AADRA2B | |
| SCHEMBL8687570 | 0.75 | IDO1 (0.45) | IDO1ADRA2AADRA2B | |
| SCHEMBL8689303 | 0.74 | IDO1 (0.47) | IDO1ADRA2AADRA2B | |
| SCHEMBL8687574 | 0.73 | CYP1A2 (0.40) | IDO1ADRA2AADRA2B | |
| SCHEMBL24026598 | 0.72 | IDO1 (0.65) | IDO1ADRA2AADRA2B | |
| SCHEMBL1241825 | 0.72 | HPGD (0.40) | ADRA2AADRA2BJAK2JAK1JAK3 | |
| SCHEMBL4065993 | 0.71 | ADRA2A (0.50) | IDO1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5807860-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS; HYPERLIPEMIA, ATHEROSCLEROSIS; ANTICHOLESTEROL AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0773218-A1 | N-(Piperazinylalkoxyphenyl)-N'phenylalkylurea derivatives as ACAT inhibitors for the treatment of atheroschlerosis | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-05-14 | — | — | EP | disclosed |